Although approved by the US Food and Drug Administration (FDA) for the treatment of CML patients harboring T315I-BCR-ABL mutation25, the third generation of TKI ponatinib encounters high rate of major arterial thrombotic and life-threatening side-effect events26. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.